

# ADMA (human) ELISA Kit

*Manufactured by Immundiagnostik AG.*

## ALX-850-323-KI01

96 wells (~80 tests)

(Version 06: December 12, 2018)

### Global Headquarters

#### ENZO LIFE SCIENCES, INC.

10 Executive Blvd.  
Farmingdale, NY 11735  
Ph: 800.942.0430  
Fax: 631.694.7501  
info-usa@enzolifesciences.com

### European Sales Office

#### ENZO LIFE SCIENCES (ELS) AG

Industriestrasse 17  
CH-4415 Lausen, Switzerland  
Ph: +41 61 926 8989  
Fax: +41 61 926 8979  
info-eu@enzolifesciences.com

### LOCAL EUROPEAN OFFICES

#### Belgium, The Netherlands & Luxembourg

Enzo Life Sciences BVBA  
Avenue Louise 65 / Box 11  
1050 Bruxelles  
Belgium  
Ph: +32 3 466 0420  
Fax: +32 3 808 7033  
info-be@enzolifesciences.com

#### Germany

Enzo Life Sciences GmbH  
Basler Strasse 57a  
DE-79540 Lörrach  
Germany  
Ph: +49 7621 5500 526  
Fax: +49 7621 5500 527  
info-de@enzolifesciences.com

#### France

Enzo Life Sciences (ELS) AG  
Branch Office Lyon  
13, avenue Albert Einstein,  
F-69100 Villeurbanne, France  
Ph: +33 472 440 655  
Fax: +33 481 680 254  
info-fr@enzolifesciences.com

#### UK & Ireland

Enzo Life Sciences (UK) Ltd.  
1 Colleton Crescent  
Exeter EX2 4DG  
Ph: 0845 601 1488 (UK customers)  
Ph: +44 1392 825900  
Fax: +44 1392 825910  
info-uk@enzolifesciences.com

[www.enzolifesciences.com](http://www.enzolifesciences.com)

**For laboratory use only. Not for human or diagnostic use.**


Manual

# ADMA ELISA

*For the in vitro determination of ADMA in human serum, citrate and EDTA plasma*

Valid from 2018-12-12

**REF** K 7828



**IVD** **CE**



**Immundiagnostik AG**, Stubenwald-Allee 8a, 64625 Bensheim, Germany

Tel.: +49 6251 70190-0

Fax: + 49 6251 849430

e.mail: [info@immundiagnostik.com](mailto:info@immundiagnostik.com)

[www.Immundiagnostik.com](http://www.Immundiagnostik.com)

## 1. INTENDED USE

This Immundiagnostik assay is intended for the quantitative determination of asymmetric dimethyl-L-arginine (ADMA) in human serum, citrate and EDTA plasma. For *in vitro* diagnostic use only.

## 2. INTRODUCTION

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO-synthase. It is formed during proteolysis of methylated proteins and removed by renal excretion or metabolic degradation by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). Several cell types, including human endothelial and tubular cells are capable of synthesizing and metabolizing ADMA. Elevated ADMA concentrations in the blood are found in numerous diseases associated with endothelial dysfunction. For example, elevated ADMA levels in blood of dialysis patients correlate significantly with the degree of arteriosclerosis and cardiovascular risk. Furthermore, elevated ADMA levels are found in patients with hypercholesterolemia, hypertension, arteriosclerosis, chronic renal failure and chronic heart failure, and are associated with restrictions in endothelial vasodilatation.

During the last years, the important clinical relevance of the regulation of vascular tone and structure by nitric oxide (NO) has been shown. Moreover, there were reports that human endothelial cells produce ADMA as well as nitric oxide, which points to an endogenous endothelial NO-regulation by ADMA. Therefore it was assumed that hypertension, arteriosclerosis and immunological dysfunction in patients with chronic renal failure are connected to a dysfunction of the L-arginine/NO-metabolism and to ADMA accumulation. The reasons for the deregulation of the L-arginine/NO-metabolism could only partially be elucidated. Certainly, there are multiple factors involved in the L-arginine/NO-metabolism regulation as for example elevation of free superoxide radicals ( $O_2^-$ ), ADMA accumulation and reduced NO-synthase activity.

Prospective clinical studies of the last years demonstrate the increased importance of ADMA as a novel cardiovascular risk factor.

### Indication

- Arteriosclerosis
- Hypertension
- Chronic heart failure
- Coronary artery disease
- Hypercholesterolemia

- Chronic renal failure
- Diabetes mellitus
- Peripheral arterial occlusive disease

### 3. MATERIAL SUPPLIED

Cat. No.	Label	Kit Components	Quantity
K 7828	PLATE	Microtiter plate, pre-coated	12 x 8 wells
K 7828	STD	Standards, ready-to-use (0, 0.1, 0.25, 0.5, 1.0, 2.0 $\mu\text{mol/l}$ )	6 x 1 ml
K 7828	CTRL 1	Control, ready-to-use (see specification for range)	1 x 1 ml
K 7828	CTRL 2	Control, ready-to-use (see specification for range)	1 x 1 ml
K 0006.C.100	WASHBUF A	Wash buffer concentrate, 10x	2 x 100 ml
K 7828	AB	ADMA antibody, lyophilised	1 vial
K 7828	CONJ	Conjugate, ready-to-use	1 x 12 ml
K 0012.15	DERBUF	Reaction buffer, ready-to-use	1 x 15 ml
K 7828	DER	Derivatisation reagent, lyophilised	1 x 100 mg
K 0008.07	DMSO	Dimethylsulfoxide (DMSO)	1 x 7 ml
K 0013.28	CODIL	Dilution buffer after derivatisation, ready-to-use	1 x 28 ml
K 0002.15	SUB	Substrate (tetramethylbenzidine), ready-to-use	1 x 15 ml
K 0003.15	STOP	Stop solution, ready-to-use	1 x 15 ml

For reorders of single components, use the catalogue number followed by the label as product number.

### 4. MATERIAL REQUIRED BUT NOT SUPPLIED

- Ultra pure water\*
- Calibrated precision pipets and 10-1000  $\mu\text{l}$  tips
- Foil to cover the microtiter plate
- Horizontal microtiter plate shaker
- Multi-channel pipets or repeater pipets

- Vortex
- Centrifuge, 3000 g
- Standard laboratory glass or plastic vials, cups, etc.
- Microtiter plate reader (required filters see chapter 7)

\* Immundiagnostik AG recommends the use of Ultra Pure Water (Water Type 1; ISO 3696), which is free of undissolved and colloidal ions and organic molecules (free of particles > 0.2 µm) with an electrical conductivity of 0.055 µS/cm at 25 °C (≥18.2 MΩ cm).

## 5. STORAGE AND PREPARATION OF REAGENTS

- To run the assay more than once, ensure that reagents are stored at the conditions stated on the label.
- **Preparation of the wash buffer:** The **wash buffer concentrate (WASHBUF A)** has to be diluted with ultra pure water **1:10** before use (100 ml WASHBUF A + 900 ml ultra pure water), mix well. Crystals could occur due to high salt concentration in the concentrate. Before dilution, the crystals have to be redissolved at room temperature or in a water bath at 37 °C. The **WASHBUF A** is stable at **2-8 °C** until the expiry date stated on the label. **Wash buffer** (1:10 diluted WASHBUF A) can be stored in a closed flask at **2-8 °C for 1 month**.
- **DMSO** crystallises at 2-8 °C. Before use, bring to room temperature to dissolve the crystals.
- The **lyophilised derivatisation reagent (DER)** is stable at **2-8 °C** until the expiry date stated on the label. Bring to room temperature before opening. Reconstitute the DER (100 mg) with **6 ml DMSO**. Allow to dissolve for 10 minutes and mix thoroughly with a vortex-mixer. **The derivatisation reagent** (reconstituted DER) **can be stored at 2-8 °C for 2 months**. Bring to room temperature before reuse. Please note: DMSO attacks all plastics but not polypropylene products and laboratory glass.
- The **lyophilised ADMA antibody (AB)** is stable at **2-8 °C** until the expiry date stated on the label. Reconstitute the AB with **6 ml of wash buffer**. **ADMA antibody** (reconstituted AB) **can be stored at 2-8 °C for 2 months**.
- All other test reagents are ready-to-use. Test reagents are stable until the expiry date (see label) when stored at **2-8 °C**.

## 6. STORAGE AND PREPARATION OF SAMPLES

### Serum, citrate and EDTA plasma

- Venous fasting blood is suited for this test system. Samples are stable for one week at 2-8 °C. For longer storage keep samples frozen at -20 °C.
- Lipemic or hemolytic samples may give erroneous results and should not be used for analysis.
- The serum, citrate and EDTA plasma samples are analysed **undiluted**.  
If the sample volume is less than 50 µl, we recommend a 1:2 dilution in DERBUF (reaction buffer) (25 µl sample + 25 µl DERBUF). This dilution factor must be considered in data evaluation.
- For sample preparation, a derivatisation reagent for derivatisation of ADMA is added (see sample preparation procedure).

## 7. ASSAY PROCEDURE

### *Principle of the test*

This ELISA is designed for the quantitative determination of ADMA. The assay is based on the method of competitive enzyme linked immunoassays.

The sample preparation includes the addition of a derivatisation-reagent for ADMA derivatisation. Afterwards, the treated samples and the polyclonal ADMA-antiserum are incubated in the wells of a microtiter plate coated with ADMA-derivative (tracer). During the incubation period, the target ADMA in the sample competes with the tracer immobilized on the wall of the microtiter wells for the binding of the polyclonal antibodies.

During the second incubation step, a peroxidase-conjugated antibody is added to detect the anti-ADMA antibodies. After washing away the unbound components, tetramethylbenzidine (TMB) is added as a peroxidase substrate. Finally, the enzymatic reaction is terminated by an acidic stop solution. The colour changes from blue to yellow, and the absorbance is measured in the photometer at 450 nm. The intensity of the yellow colour is inverse proportional to the ADMA concentration in the sample; this means, high ADMA concentration in the sample reduces the concentration of tracer-bound antibodies and lowers the photometric signal. A dose response curve of the absorbance unit (optical density, OD at 450 nm) vs. concentration is generated, using the values obtained from the standard. ADMA, present in the patient samples, is determined directly from this curve.

### *Sample preparation procedure*

Bring **all reagents and samples to room temperature** (15-30 °C) and mix well. Derivatisation of standards, controls and samples is carried out in single analysis in vials (e.g. 1.5 ml vials).

We recommend preparing one derivatisation per standard, control and sample and transferring it in duplicate determinations into the wells of the microtiter plate.

1.	Add <b>200 µl standard</b> (STD), <b>200 µl control</b> (CTRL) and <b>50 µl sample</b> in the corresponding vials.
2.	Add <b>150 µl reaction buffer</b> (DERBUF) <b>only to the samples</b> .
3.	Add <b>50 µl derivatisation reagent</b> into each vial (STD, CTRL, sample), <b>mix thoroughly</b> by repeated inversion or several seconds on a vortex mixer. Incubate for <b>45 min at room temperature</b> (15-30 °C) on a <b>horizontal shaker</b> .
4.	Add <b>250 µl dilution buffer</b> (CODIL) into each vial, mix well and incubate for <b>45 min at room temperature</b> (15-30 °C) on a horizontal <b>shaker</b> .

2 x 50 µl of the derivatised standards, controls and samples are used in the ELISA as duplicates.

### *Test procedure*

Mark the positions of standards/controls/samples in duplicate on a protocol sheet.

Take as many microtiter strips as needed from the kit. Store unused strips covered at 2-8 °C. Strips are stable until expiry date stated on the label.

5.	For the analysis in duplicate take <b>2 x 50 µl</b> of the <b>derivatised standards/controls/samples</b> out of the vials and add into the respective wells of the microtiter plate.
6.	Add <b>50 µl ADMA antibody</b> into each well of the microtiter plate.
7.	Cover the strips tightly with foil and incubate <b>overnight at 2-8°C</b> .
8.	Discard the content of each well and wash <b>5 times</b> with <b>250 µl wash buffer</b> . After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.

9.	Add <b>100 µl conjugate</b> (CONJ) into each well.
10.	Cover the strips and incubate for <b>1 hour</b> at <b>room temperature</b> (15-30 °C) on a <b>horizontal shaker</b> .
11.	Discard the content of each well and wash <b>5 times</b> with <b>250 µl wash buffer</b> . After the final washing step, remove residual wash buffer by firmly tapping the plate on absorbent paper.
12.	Add <b>100 µl substrate</b> (SUB) into each well.
13.	Incubate for <b>10-14 min*</b> at room temperature (15-30 °C) in the <b>dark</b> .
14.	Add <b>100 µl stop solution</b> (STOP) into each well and mix well.
15.	Determine <b>absorption immediately</b> with an ELISA reader at <b>450 nm</b> against 620 nm (or 690 nm) as a reference. If no reference wavelength is available, read only at 450 nm. If the extinction of the highest standard exceeds the range of the photometer, absorption must be measured immediately at <b>405 nm</b> against 620 nm (690 nm) as a reference.

\* The intensity of the colour change is temperature sensitive. We recommend observing the colour change and stopping the reaction upon good differentiation.

For automated ELISA processors, the given protocol may need to be adjusted according to the specific features of the respective automated platform. For further details please contact your supplier or Immundiagnostik AG.

## 8. RESULTS

The following algorithms can be used alternatively to calculate the results. We recommend using the 4 parameter algorithm.

### 1. 4 parameter algorithm

It is recommended to use a linear ordinate for optical density and a logarithmic abscissa for concentration. When using a logarithmic abscissa, the zero standard must be specified with a value less than 1 (e.g. 0.001).

### 2. Point-to-point calculation

We recommend a linear ordinate for optical density and a linear abscissa for concentration.

### 3. Spline algorithm

We recommend a linear ordinate for optical density and a linear abscissa for concentration.


The plausibility of the pairs of values should be examined before the automatic evaluation of the results. If this option is not available with the used program, a control of the paired values should be done manually.

#### Serum, citrate and EDTA plasma

The concentrations can be determined directly from the standard curve in  $\mu\text{mol/l}$ . **No factor** is required.

Exception: Consider the dilution factor for 1:2 pre-diluted samples.

In the following, an example of a standard curve is given. Do not use it for the calculation of your results.



## 9. LIMITATIONS

Samples with an OD lower than the OD of the highest standard should be diluted with reaction buffer (DERBUF) and re-assayed. Please consider this dilution factor when calculating the results.

## 10. QUALITY CONTROL

Immundiagnostik recommends the use of external controls for internal quality control, if possible.

Control samples should be analysed with each run. Results, generated from the analysis of control samples, should be evaluated for acceptability using appropriate statistical methods. The results for the patient samples may not be valid if within the same assay one or more values of the quality control samples are outside of the acceptable limits.

### *Reference range*

Based on internal studies with samples from apparently healthy persons (n = 80), a mean value of 0.46  $\mu\text{mol/l}$  was estimated. The standard deviation was 0.085  $\mu\text{mol/l}$ . From mean value  $\pm 2 \times \text{SD}$  a normal range of 0.29 – 0.63  $\mu\text{mol/l}$  was estimated.

We recommend each laboratory to establish its own reference range.

## 11. PERFORMANCE CHARACTERISTICS

### *Precision and reproducibility*

#### **Intra-assay (n = 12)**

Sample	ADMA [ $\mu\text{mol/l}$ ]	CV [%]
1	0.29	7.5
2	0.80	6.4

#### **Inter-assay (n = 10)**

Sample	ADMA [ $\mu\text{mol/l}$ ]	CV [%]
1	0.37	3.9
2	0.68	3.5

### *Spiking recovery*

Two samples were spiked with different ADMA concentrations and measured in this assay (n = 2). The mean recovery rate for all concentrations was 101 %.

sample	spike [ $\mu\text{mol/l}$ ]	ADMA expected [ $\mu\text{mol/l}$ ]	ADMA measured [ $\mu\text{mol/l}$ ]	recovery [%]
A			0.373	
	0.3	0.673	0.665	98.8
	0.5	0.873	0.898	102.9
B			0.368	
	0.3	0.668	0.693	103.7
	0.5	0.868	0.846	97.5

### *Dilution recovery*

Two spiked samples were diluted with reaction buffer. The mean recovery rate was 108 % (n = 2).

sample	dilution	ADMA expected [ $\mu\text{mol/l}$ ]	ADMA measured [ $\mu\text{mol/l}$ ]	recovery [%]
A			0.904	
	1:2	0.452	0.484	107.1
	1:3	0.301	0.317	105.2
	1:4	0.226	0.263	116.4
B			0.846	
	1:2	0.452	0.393	86.9
	1:3	0.282	0.315	111.7
	1:4	0.212	0.251	118.7

### *Analytical sensitivity*

Limit of blank, LoB 0.12  $\mu\text{mol/l}$

Limit of detection, LoD 0.15  $\mu\text{mol/l}$

Limit of quantitation, LoQ 0.16  $\mu\text{mol/l}$

The evaluation was performed according to the CLSI guideline EP-17-A2. The specified accuracy goal for the LoQ was 20 % CV.


## Specificity

Specificity was tested by measuring the cross-reactivity against compounds with structural similarity to ADMA. The specificity is calculated in percent in relation to the ADMA binding activity.

L-Arginin	< 0.01 %
SDMA	< 0.2 %

## Correlation with HPLC-MS

10 samples were measured with this ELISA and HPLC-MS. The correlation was  $r = 0.98$ .



## 12. PRECAUTIONS

- All reagents in the kit package are for *in vitro* diagnostic use only.
- Human materials used in kit components were tested and found to be negative for HIV, Hepatitis B and Hepatitis C. However, for safety reasons, all kit components should be treated as potentially infectious.
- Kit reagents contain sodium azide or ProClin as bactericides. Sodium azide and ProClin are toxic. Substrates for the enzymatic colour reactions are toxic and carcinogenic. Avoid contact with skin or mucous membranes.
- The stop solution consists of diluted sulfuric acid, a strong acid. Although diluted, it still must be handled with care. It can cause burns and should be

handled with gloves, eye protection, and appropriate protective clothing. Any spill should be wiped up immediately with copious quantities of water. Do not breathe vapour and avoid inhalation.

### **13. TECHNICAL HINTS**

- Do not interchange different lot numbers of any kit component within the same assay. Furthermore, we recommend not assembling wells of different microtiter plates for analysis, even if they are of the same batch.
- Control samples should be analysed with each run.
- Reagents should not be used beyond the expiration date stated on the kit label.
- Substrate solution should remain colourless until use.
- To ensure accurate results, proper adhesion of plate sealers during incubation steps is necessary.
- Avoid foaming when mixing reagents.
- Do not mix plugs and caps from different reagents.
- The assay should always be performed according to the enclosed manual.

### **14. GENERAL NOTES ON THE TEST AND TEST PROCEDURE**

- This assay was produced and distributed according to the IVD guidelines of 98/79/EC.
- The guidelines for medical laboratories should be followed.
- Incubation time, incubation temperature, and pipetting volumes of the components are defined by the producer. Any variation of the test procedure, which is not coordinated with the producer, may influence the results of the test. Immundiagnostik AG can therefore not be held responsible for any damage resulting from incorrect use.
- Warranty claims and complaints regarding deficiencies must be logged within 14 days after receipt of the product. The product should be sent to Immundiagnostik AG along with a written complaint.

## 15. REFERENCES

### *General literature*

Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF, Cooke JP. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. *Circulation* 1998; **98**: 1842 – 1847

Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. *Cardiovasc Res.* 2003; **59**: 824-833

Kielstein JT, Böger RH, Bode-Böger SM, et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. *J Am Soc Nephrol.* 1999; **10**: 594 – 600

Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. *Eur Heart J.* 2003; **24**: 1912-1919.

Nijveldt RJ, Teerlink T, Van der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA, van Leeuwen PA. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. *Clin Nutr.* 2003; **22**: 23-30

Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaidis KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. *Lancet* 2003; **361**: 1511-1517

Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. *J Am Med Assoc.* 2002; **287**: 1420-1426

Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. *Lancet* 1992; **339**: 572 – 575

Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich JC, Böger RH. Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). *Lancet* 2001; **358**: 2113-2117

### *Literature using Immundiagnostik ADMA ELISA*

Aktoz T, Aktoz M, Tatlı E, Kaplan M, Turan FN, Barutcu A, Atakan IH, Demir M, Altun A. Assessment of the Relationship between Asymmetric Dimethylarginine

and Severity of Erectile Dysfunction and Coronary Artery Disease. *Int Urol Nephrol*. Dec;**42**(4):873-9. doi: 10.1007/s11255-009-9696-9

Ayer JG, Harmer JA, Xuan W, Toelle B, Webb K, Almqvist C, Marks GB, Celermajer DS. Dietary Supplementation with N-3 Polyunsaturated Fatty Acids in Early Childhood: Effects on Blood Pressure and Arterial Structure and Function at Age 8 Y. *Am J Clin Nutr*. 2009 Aug;**90**(2):438-46. doi: 10.3945/ajcn.2009.27811

Bang OY, Chung J, Kim SJ, Chung J et al. Caveolin-1 , Ring finger protein 213, and endothelial function in Moyamoya disease. *Int J Stroke*. 2016;**0**(0):1-10. doi:10.1177/1747493016662039

Brenner T, Fleming TH, Rosenhagen C, Krauser U, Mieth M, Bruckner T, Martin E, Nawroth PP, Weigand MA, Bierhaus A, Hofer S. L-arginine and asymmetric dimethylarginine are early predictors for survival in septic patients with acute liver failure. *Mediators Inflamm*. **2012**: 210454. doi:10.1155/2012/210454.

Celik M, Cerrah S, Arabul M, Akalin A. Relation of asymmetric dimethylarginine levels to macrovascular disease and inflammation markers in type 2 diabetic patients. *J Diabetes Res*. **2014**: 139215

Kurtoglu E, Balta S, Sincer I, Altas Y, Atas H, Yilmaz M, Korkmaz H, Erdem K, Akturk E, Demirkol S, Can C. Comparison of Effects of Rosuvastatin versus Atorvastatin Treatment on Plasma Levels of Asymmetric Dimethylarginine in Patients with Hyperlipidemia Having Coronary Artery Disease. *Angiology*. 2014 **65**(9):788–93. doi:10.1177/0003319713507333

Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD. Cumulative inflammation associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study. *Rheumatology (Oxford, England)*. **2014**;(September 2014):1-8. doi:10.1093/rheumatology/keu349

**Used symbols:**

	Temperature limitation		Catalogue Number
	In Vitro Diagnostic Medical Device		To be used with
	Manufacturer		Contains sufficient for <n> tests
	Lot number		Use by
	Attention		Consult instructions for use
	Consult specification data sheet		